Synosia gains cognitive disorder compound
This article was originally published in Scrip
Executive Summary
The private Swiss company Synosia has acquired another new-generation 5-HT6 antagonist for cognitive disorders such as Alzheimer's disease and schizophrenia from Roche for an undisclosed sum. The Phase I product has potential to be a best-in-class molecule.